APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antifibrotic Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antifibrotic Drug Market Outlook and Growth Opportunities 2026

20 December 2025203 pages

Choose your research edition.

Industry ResearchAntifibrotic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Antifibrotic Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Antifibrotic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antifibrotic Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Antifibrotic Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Antifibrotic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antifibrotic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antifibrotic Drug market include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Beacon Pharma, Boehringer Ingelheim, Eskayef Pharmaceuticals, ScieGen Pharmaceuticals, Gyre Pharmaceuticals and Kawin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antifibrotic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antifibrotic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antifibrotic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antifibrotic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Antifibrotic Drug Segment by Company

Accord Healthcare

Amneal Pharmaceuticals

Apotex

Beacon Pharma

Boehringer Ingelheim

Eskayef Pharmaceuticals

ScieGen Pharmaceuticals

Gyre Pharmaceuticals

Kawin

Roche

Qilu Pharmaceutical

PuraCap

Sandoz

CSPC Pharmaceutical Group

Kelun Pharmaceutical

Teva

Antifibrotic Drug Segment by Type

Nintedanib

Pirfenidone

Antifibrotic Drug Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Antifibrotic Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antifibrotic Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antifibrotic Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antifibrotic Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antifibrotic Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antifibrotic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antifibrotic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antifibrotic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antifibrotic Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antifibrotic Drug industry.

Chapter 3: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antifibrotic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antifibrotic Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antifibrotic Drug Industry Trends Table 2. Antifibrotic Drug Industry Drivers Table 3. Antifibrotic Drug Industry Opportunities and Challenges Table 4. Antifibrotic Drug Industry Restraints Table 5. Global Antifibrotic Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antifibrotic Drug Revenue Share by Company (2021-2026) Table 7. Global Antifibrotic Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Antifibrotic Drug Sales Volume Share by Company (2021-2026) Table 9. Global Antifibrotic Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Antifibrotic Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antifibrotic Drug Key Company Manufacturing Base & Headquarters Table 12. Global Antifibrotic Drug Company, Product Type & Application Table 13. Global Antifibrotic Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antifibrotic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Nintedanib Table 18. Significant Companies of Pirfenidone Table 19. Global Antifibrotic Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Antifibrotic Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Antifibrotic Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Antifibrotic Drug Sales Volume Share by Type (2021-2026) Table 23. Global Antifibrotic Drug Sales Volume Share by Type (2027-2032) Table 24. Global Antifibrotic Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antifibrotic Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antifibrotic Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antifibrotic Drug Sales Value Share by Type (2021-2026) Table 28. Global Antifibrotic Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Other Table 32. Global Antifibrotic Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Antifibrotic Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global Antifibrotic Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global Antifibrotic Drug Sales Volume Share by Application (2021-2026) Table 36. Global Antifibrotic Drug Sales Volume Share by Application (2027-2032) Table 37. Global Antifibrotic Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antifibrotic Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Antifibrotic Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Antifibrotic Drug Sales Value Share by Application (2021-2026) Table 41. Global Antifibrotic Drug Sales Value Share by Application (2027-2032) Table 42. Global Antifibrotic Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Antifibrotic Drug Sales by Region (2021-2026) & (k units) Table 44. Global Antifibrotic Drug Sales Market Share by Region (2021-2026) Table 45. Global Antifibrotic Drug Sales by Region (2027-2032) & (k units) Table 46. Global Antifibrotic Drug Sales Market Share by Region (2027-2032) Table 47. Global Antifibrotic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antifibrotic Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Antifibrotic Drug Sales Value Share by Region (2021-2026) Table 50. Global Antifibrotic Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Antifibrotic Drug Sales Value Share by Region (2027-2032) Table 52. Global Antifibrotic Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Antifibrotic Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Antifibrotic Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 57. Global Antifibrotic Drug Sales Market Share by Country (2021-2026) Table 58. Global Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 59. Global Antifibrotic Drug Sales Market Share by Country (2027-2032) Table 60. Global Antifibrotic Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Antifibrotic Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Antifibrotic Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Antifibrotic Drug Sales Value Market Share by Country (2027-2032) Table 64. Accord Healthcare Company Information Table 65. Accord Healthcare Business Overview Table 66. Accord Healthcare Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Accord Healthcare Antifibrotic Drug Product Portfolio Table 68. Accord Healthcare Recent Development Table 69. Amneal Pharmaceuticals Company Information Table 70. Amneal Pharmaceuticals Business Overview Table 71. Amneal Pharmaceuticals Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio Table 73. Amneal Pharmaceuticals Recent Development Table 74. Apotex Company Information Table 75. Apotex Business Overview Table 76. Apotex Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Apotex Antifibrotic Drug Product Portfolio Table 78. Apotex Recent Development Table 79. Beacon Pharma Company Information Table 80. Beacon Pharma Business Overview Table 81. Beacon Pharma Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Beacon Pharma Antifibrotic Drug Product Portfolio Table 83. Beacon Pharma Recent Development Table 84. Boehringer Ingelheim Company Information Table 85. Boehringer Ingelheim Business Overview Table 86. Boehringer Ingelheim Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Boehringer Ingelheim Antifibrotic Drug Product Portfolio Table 88. Boehringer Ingelheim Recent Development Table 89. Eskayef Pharmaceuticals Company Information Table 90. Eskayef Pharmaceuticals Business Overview Table 91. Eskayef Pharmaceuticals Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio Table 93. Eskayef Pharmaceuticals Recent Development Table 94. ScieGen Pharmaceuticals Company Information Table 95. ScieGen Pharmaceuticals Business Overview Table 96. ScieGen Pharmaceuticals Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio Table 98. ScieGen Pharmaceuticals Recent Development Table 99. Gyre Pharmaceuticals Company Information Table 100. Gyre Pharmaceuticals Business Overview Table 101. Gyre Pharmaceuticals Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio Table 103. Gyre Pharmaceuticals Recent Development Table 104. Kawin Company Information Table 105. Kawin Business Overview Table 106. Kawin Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Kawin Antifibrotic Drug Product Portfolio Table 108. Kawin Recent Development Table 109. Roche Company Information Table 110. Roche Business Overview Table 111. Roche Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Roche Antifibrotic Drug Product Portfolio Table 113. Roche Recent Development Table 114. Qilu Pharmaceutical Company Information Table 115. Qilu Pharmaceutical Business Overview Table 116. Qilu Pharmaceutical Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Qilu Pharmaceutical Antifibrotic Drug Product Portfolio Table 118. Qilu Pharmaceutical Recent Development Table 119. PuraCap Company Information Table 120. PuraCap Business Overview Table 121. PuraCap Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. PuraCap Antifibrotic Drug Product Portfolio Table 123. PuraCap Recent Development Table 124. Sandoz Company Information Table 125. Sandoz Business Overview Table 126. Sandoz Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Sandoz Antifibrotic Drug Product Portfolio Table 128. Sandoz Recent Development Table 129. CSPC Pharmaceutical Group Company Information Table 130. CSPC Pharmaceutical Group Business Overview Table 131. CSPC Pharmaceutical Group Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio Table 133. CSPC Pharmaceutical Group Recent Development Table 134. Kelun Pharmaceutical Company Information Table 135. Kelun Pharmaceutical Business Overview Table 136. Kelun Pharmaceutical Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Kelun Pharmaceutical Antifibrotic Drug Product Portfolio Table 138. Kelun Pharmaceutical Recent Development Table 139. Teva Company Information Table 140. Teva Business Overview Table 141. Teva Antifibrotic Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Teva Antifibrotic Drug Product Portfolio Table 143. Teva Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Antifibrotic Drug Distributors List Table 147. Antifibrotic Drug Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Antifibrotic Drug Product Image Figure 2. Global Antifibrotic Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antifibrotic Drug Sales (2021-2032) & (k units) Figure 5. Global Antifibrotic Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Antifibrotic Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Nintedanib Image Figure 10. Pirfenidone Image Figure 11. Global Antifibrotic Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Antifibrotic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antifibrotic Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Antifibrotic Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antifibrotic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antifibrotic Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Antifibrotic Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Antifibrotic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Antifibrotic Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Antifibrotic Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Antifibrotic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Antifibrotic Drug Sales Value Share by Application (2021-2032) Figure 26. Global Antifibrotic Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Antifibrotic Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Antifibrotic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Antifibrotic Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Antifibrotic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Antifibrotic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Antifibrotic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Antifibrotic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Antifibrotic Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Antifibrotic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Antifibrotic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Antifibrotic Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Antifibrotic Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Nintedanib
  • Pirfenidone
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Apotex
  • Beacon Pharma
  • Boehringer Ingelheim
  • Eskayef Pharmaceuticals
  • ScieGen Pharmaceuticals
  • Gyre Pharmaceuticals
  • Kawin
  • Roche
  • Qilu Pharmaceutical
  • PuraCap
  • Sandoz
  • CSPC Pharmaceutical Group
  • Kelun Pharmaceutical
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antifibrotic Drug Sales Value (2021-2032)
  4. 1.2.2 Global Antifibrotic Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Antifibrotic Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antifibrotic Drug Market Dynamics
  1. 2.1 Antifibrotic Drug Industry Trends
  2. 2.2 Antifibrotic Drug Industry Drivers
  3. 2.3 Antifibrotic Drug Industry Opportunities and Challenges
  4. 2.4 Antifibrotic Drug Industry Restraints
3 Antifibrotic Drug Market by Company
  1. 3.1 Global Antifibrotic Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antifibrotic Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antifibrotic Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Antifibrotic Drug Average Price by Company (2021-2026)
  5. 3.5 Global Antifibrotic Drug Company Ranking (2024-2026)
  6. 3.6 Global Antifibrotic Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Antifibrotic Drug Company Product Type and Application
  8. 3.8 Global Antifibrotic Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antifibrotic Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antifibrotic Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antifibrotic Drug Market by Type
  1. 4.1 Antifibrotic Drug Type Introduction
  2. 4.1.1 Nintedanib
  3. 4.1.2 Pirfenidone
  4. 4.2 Global Antifibrotic Drug Sales Volume by Type
  5. 4.2.1 Global Antifibrotic Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antifibrotic Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antifibrotic Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antifibrotic Drug Sales Value by Type
  9. 4.3.1 Global Antifibrotic Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antifibrotic Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antifibrotic Drug Sales Value Share by Type (2021-2032)
5 Antifibrotic Drug Market by Application
  1. 5.1 Antifibrotic Drug Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Antifibrotic Drug Sales Volume by Application
  6. 5.2.1 Global Antifibrotic Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antifibrotic Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antifibrotic Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antifibrotic Drug Sales Value by Application
  10. 5.3.1 Global Antifibrotic Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antifibrotic Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antifibrotic Drug Sales Value Share by Application (2021-2032)
6 Antifibrotic Drug Regional Sales and Value Analysis
  1. 6.1 Global Antifibrotic Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antifibrotic Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Antifibrotic Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Antifibrotic Drug Sales by Region (2027-2032)
  5. 6.3 Global Antifibrotic Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antifibrotic Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antifibrotic Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antifibrotic Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Antifibrotic Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antifibrotic Drug Sales Value (2021-2032)
  12. 6.6.2 North America Antifibrotic Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antifibrotic Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Antifibrotic Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antifibrotic Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antifibrotic Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antifibrotic Drug Sales Value (2021-2032)
  21. 6.9.2 South America Antifibrotic Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antifibrotic Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antifibrotic Drug Sales Value Share by Country, 2025 VS 2032
7 Antifibrotic Drug Country-level Sales and Value Analysis
  1. 7.1 Global Antifibrotic Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antifibrotic Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antifibrotic Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Antifibrotic Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Antifibrotic Drug Sales by Country (2027-2032)
  6. 7.4 Global Antifibrotic Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antifibrotic Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antifibrotic Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antifibrotic Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antifibrotic Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antifibrotic Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Antifibrotic Drug Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Amneal Pharmaceuticals
  8. 8.2.1 Amneal Pharmaceuticals Company Information
  9. 8.2.2 Amneal Pharmaceuticals Business Overview
  10. 8.2.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals Recent Developments
  13. 8.3 Apotex
  14. 8.3.1 Apotex Company Information
  15. 8.3.2 Apotex Business Overview
  16. 8.3.3 Apotex Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Apotex Antifibrotic Drug Product Portfolio
  18. 8.3.5 Apotex Recent Developments
  19. 8.4 Beacon Pharma
  20. 8.4.1 Beacon Pharma Company Information
  21. 8.4.2 Beacon Pharma Business Overview
  22. 8.4.3 Beacon Pharma Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Beacon Pharma Antifibrotic Drug Product Portfolio
  24. 8.4.5 Beacon Pharma Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 Eskayef Pharmaceuticals
  32. 8.6.1 Eskayef Pharmaceuticals Company Information
  33. 8.6.2 Eskayef Pharmaceuticals Business Overview
  34. 8.6.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
  36. 8.6.5 Eskayef Pharmaceuticals Recent Developments
  37. 8.7 ScieGen Pharmaceuticals
  38. 8.7.1 ScieGen Pharmaceuticals Company Information
  39. 8.7.2 ScieGen Pharmaceuticals Business Overview
  40. 8.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
  42. 8.7.5 ScieGen Pharmaceuticals Recent Developments
  43. 8.8 Gyre Pharmaceuticals
  44. 8.8.1 Gyre Pharmaceuticals Company Information
  45. 8.8.2 Gyre Pharmaceuticals Business Overview
  46. 8.8.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
  48. 8.8.5 Gyre Pharmaceuticals Recent Developments
  49. 8.9 Kawin
  50. 8.9.1 Kawin Company Information
  51. 8.9.2 Kawin Business Overview
  52. 8.9.3 Kawin Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kawin Antifibrotic Drug Product Portfolio
  54. 8.9.5 Kawin Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Roche Antifibrotic Drug Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Qilu Pharmaceutical
  62. 8.11.1 Qilu Pharmaceutical Company Information
  63. 8.11.2 Qilu Pharmaceutical Business Overview
  64. 8.11.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
  66. 8.11.5 Qilu Pharmaceutical Recent Developments
  67. 8.12 PuraCap
  68. 8.12.1 PuraCap Company Information
  69. 8.12.2 PuraCap Business Overview
  70. 8.12.3 PuraCap Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 PuraCap Antifibrotic Drug Product Portfolio
  72. 8.12.5 PuraCap Recent Developments
  73. 8.13 Sandoz
  74. 8.13.1 Sandoz Company Information
  75. 8.13.2 Sandoz Business Overview
  76. 8.13.3 Sandoz Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sandoz Antifibrotic Drug Product Portfolio
  78. 8.13.5 Sandoz Recent Developments
  79. 8.14 CSPC Pharmaceutical Group
  80. 8.14.1 CSPC Pharmaceutical Group Company Information
  81. 8.14.2 CSPC Pharmaceutical Group Business Overview
  82. 8.14.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
  84. 8.14.5 CSPC Pharmaceutical Group Recent Developments
  85. 8.15 Kelun Pharmaceutical
  86. 8.15.1 Kelun Pharmaceutical Company Information
  87. 8.15.2 Kelun Pharmaceutical Business Overview
  88. 8.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
  90. 8.15.5 Kelun Pharmaceutical Recent Developments
  91. 8.16 Teva
  92. 8.16.1 Teva Company Information
  93. 8.16.2 Teva Business Overview
  94. 8.16.3 Teva Antifibrotic Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Teva Antifibrotic Drug Product Portfolio
  96. 8.16.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antifibrotic Drug Value Chain Analysis
  2. 9.1.1 Antifibrotic Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antifibrotic Drug Sales Mode & Process
  6. 9.2 Antifibrotic Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antifibrotic Drug Distributors
  9. 9.2.3 Antifibrotic Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst